Picture of Sartorius Stedim Biotech SA logo

DIM — Sartorius Stedim Biotech SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Brief: Sartorius Stedim Biotech Confirms And Partially Refines Guidance For 2026

BRIEF-Sartorius Stedim Biotech Confirms And Partially Refines Guidance For 2026

- Sartorius Stedim Biotech STDM.PA:

  • SARTORIUS STEDIM BIOTECH 9M ADJUSTED EBITDA EUR 716 MILLION

  • SARTORIUS STEDIM BIOTECH 9M CASH FLOW FROM OPERATING ACTIVITIES EUR 497.6 MILLION

  • SARTORIUS STEDIM BIOTECH 9M ADJUSTED NET INCOME EUR 349.6 MILLION

  • SARTORIUS STEDIM BIOTECH 9M REVENUE EUR 2,289.2 MILLION

  • SARTORIUS STEDIM BIOTECH 9M ADJUSTED EPS EUR 3.59

  • SARTORIUS STEDIM BIOTECH 9M NET INCOME EUR 276.6 MILLION

  • SARTORIUS STEDIM BIOTECH 9M EPS EUR 2.84

  • MANAGEMENT CONFIRMS AND PARTIALLY REFINES GUIDANCE FOR 2026

  • CONFIRMS ITS SALES AND PROFITABILITY GUIDANCE FOR FY AND REFINES EXPECTED RATIO OF CAPITAL EXPENDITURE TO SALES REVENUE

  • OUTLOOK 2026: RATIO OF CAPITAL EXPENDITURE TO SALES REVENUE IS NOW EXPECTED TO BE AROUND 13 PERCENT

  • OUTLOOK 2026: RATIO OF NET DEBT TO UNDERLYING EBITDA SHOULD DECREASE TO SLIGHTLY ABOVE 2 (PY: 2.38)

Source text: ID:nEQRj6b9a

Further company coverage: [STDM.PA]


(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Sartorius Stedim Biotech SA

See all news